Back

Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled

29 August 2022 (14:18 - 14:37)
Organised by:
Congress Presentation Part of: How to treat HFpEF in 2022 and beyond Comorbidities ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

3 More presentations in this session

Presentation thumbnail
Treating HFpEF: State of the art 2022
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial
Doctor K. Bunting (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
How to treat HFpEF in 2022 and beyond
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:18 CET
You may be interested in
thumbnail
Congress Presentation
Effects of Dapagliflozin in Patients with Heart Failure and Deterioration of Kidney Function Below eGFR 25ml/min/1.73m^2
thumbnail
Congress Presentation
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources